The study commencement is based on previous clinical safety and efficacy data, along with robust preclinical evidence.

在当地时间9月15日的头颈肿瘤优选论文专场，复旦大学附属肿瘤医院胡超苏教授就“Sequential chemoradiotherapy versus induction chemotherapy plus concurrent ...

Patients have experienced life-changing improvements in their vision thanks to a new gene therapy developed by University of ...

Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...

近日，复星医药自主研发的治疗ALK 阳性非小细胞肺癌（NSCLC）的创新药复瑞替尼（Foritinib，SAF-189s）III期研究期中分析结果于2024年世界肺癌大会（WCLC）期间重磅发布。

该研究结果表明复瑞替尼整体疗效良好，相比于克唑替尼治疗可使PFS显著改善，使CNS进展风险降低，且其安全性可控，治疗后未出现新的安全性信号。 近日，复星医药自主研发的治疗ALK 阳性非小细胞肺癌（NSCLC）的创新药复瑞替尼（Foritinib，SAF-189s）III期研究 ...

Jupiter Endovascular has treated the first two patients in the SPIRARE I study, utilising its Vertex pulmonary embolectomy ...

In IVF treatment, embryos are traditionally transferred to the uterus three days after fertilization. Due to improvements in ...

There were no differences in quality of life, symptoms, hospital admissions or mortality between a group of patients with pulmonary disease and low oxygen levels in the blood that received oxygen ...

Richter transformation describes the development of an aggressive lymphoma in patients with chronic lymphocytic leukaemia, ...